ALEBUND-B (09637) delivered its inaugural interim results on August 26, marking a significant milestone since its listing, with revenue scaling to 8.6 times the figure reported in the same period last year. Beyond the headline numbers, this financial report arrives at a pivotal moment when global innovation in kidney disease therapeutics is accelerating its commercial adoption, prompting a renewed valuation of high-quality assets. This context brings the growth trajectory of China's vertical-specialty biopharmaceutical model, as exemplified by ALEBUND, into sharper focus.
A key indicator of this global momentum comes from U.S.-based kidney disease specialist Travere Therapeutics, which reported that its lead product FILSPARI generated net U.S. sales of $141.1 million in the second quarter of 2026, a 96% year-over-year surge. This growth was fueled by the launch of the drug for a new indication, FSGS, and expanding use in IgA nephropathy, leading to 2,012 new patient starts during the quarter. Following this announcement, Travere's stock climbed approximately 14% in after-hours trading. Having secured FDA approval for FSGS in April, FILSPARI became the first authorized therapy for this condition, which has long lacked targeted treatment options. Travere's performance underscores a critical principle: innovative kidney disease drugs addressing clear unmet needs can successfully navigate the full arc from R&D and regulatory approval to market access and commercialization, evolving into substantial commercial assets.
This trend is not an isolated event. In 2023, Novartis acquired Chinook Therapeutics in a deal valued at up to $3.5 billion. The following year, Calliditas, the developer of the IgA nephropathy treatment Nefecon, was acquired by Astellas for approximately $1.1 billion. Additionally, Ardelyx received FDA approval in 2023 for XPHOZAH, a first-in-class NHE3 inhibitor that offers a novel mechanism for managing hyperphosphatemia in dialysis patients, distinct from traditional phosphate binders. These examples collectively illustrate that as drug pricing aligns with clinical value, biopharmaceutical companies with deep expertise in specific therapeutic verticals, coupled with robust R&D pipelines and specialized commercialization capabilities, are gaining greater industry recognition and strategic value.
Within this global landscape, ALEBUND's first interim report delineates the growth blueprint of a Chinese vertical-specialty biopharma, building upon validated international models.
Validating the "Big Business" Potential of Kidney Disease Innovation
Data from a Global Burden of Disease study published in The Lancet indicates that approximately 697.5 million people worldwide were living with chronic kidney disease (CKD) in 2017, reflecting a prevalence rate of about 9.1% and accounting for roughly 1.2 million deaths. In China alone, the patient population is estimated at 132.3 million. Beyond the sheer patient numbers, CKD is characterized by its lengthy disease course, multiple comorbidities, and the need for long-term management. Patients may sequentially face proteinuria, declining kidney function, renal anemia, hyperphosphatemia, and eventually dialysis, creating a sustained demand for therapies that address each stage of the disease.
The International Society of Nephrology has highlighted significant gaps in early detection, standardized treatment protocols, and access to renal replacement therapy globally. The KDIGO 2024 guidelines further emphasize strategies for delaying disease progression through risk stratification, early intervention, and complication management. This indicates that the industry's growth is driven not only by the expanding patient base but also by increasing diagnosis and treatment rates and the adoption of more advanced therapeutic regimens. While Travere has demonstrated the commercial potential of products for rare glomerular diseases, and the acquisitions of Calliditas and Chinook underscore the strategic value of differentiated kidney disease assets, Ardelyx has proven that novel mechanisms can carve out new treatment categories beyond conventional approaches.
ALEBUND's differentiation lies in its strategic choice to not focus on a single indication. Instead, it has built a diversified portfolio matrix that addresses the entire spectrum of CKD, progressing from commercialized products to core assets in the registration stage, global clinical-stage programs, and early-stage pipelines targeting disease modification.
First Interim Report Reveals a "Two-Pronged" Value Delivery
During the reporting period, ALEBUND-B recorded total revenue of RMB 104.2 million, an 8.6-fold increase compared to the same period last year. A closer look at the revenue composition reveals two distinct income streams that highlight the company's dual growth capabilities. Product sales from Mircera® contributed RMB 24.8 million, representing a year-on-year growth of approximately 105%, which validates the company's ability to execute on hospital access, academic promotion, and commercial rollout within the nephrology field. Concurrently, the licensing of ex-Greater China rights for AP306 generated RMB 79.3 million in licensing revenue, signifying that the value of its investigational assets has been recognized and priced by an international industry partner.
These two revenue types are fundamentally different in nature but collectively address the two core challenges facing any biotech: achieving sustained product uptake within hospitals on the commercial front, and securing global market validation for its innovative pipeline on the R&D front. While licensing revenue is not a recurring product sale, its strategic importance lies in converting long-term R&D assets into immediate revenue and industry resources. ALEBUND retains all rights to AP306 in Greater China while leveraging its partnership with R1 Therapeutics to advance development overseas. This approach embodies a capital-efficient globalization strategy that preserves core market rights, attracts global resources, and shares development costs. As of the end of the reporting period, the company held cash and time deposits totaling approximately RMB 1.393 billion. This robust financial position is sufficient to support the regulatory submission and commercialization preparation for AP301, the global clinical advancement of AP306, and the parallel progression of earlier-stage pipeline assets like AP303 and AP308.
This distinguishes ALEBUND as a biopharma rather than a pure R&D-stage biotech. Its value creation is no longer solely dependent on clinical data catalysts but is increasingly derived from a self-reinforcing cycle encompassing product sales, asset licensing, global partnerships, and continuous research and development.
From "Today's Revenue" to "Tomorrow's Opportunities"
ALEBUND's pipeline can be viewed as a value growth curve with clearly defined time horizons. Mircera® represents the "present." Its doubling sales revenue not only provides stable current cash flow but has also allowed the company to establish its nephrology hospital network, physician awareness, and marketing infrastructure ahead of schedule. This mature, specialized channel is directly reusable for future in-house products, significantly shortening their launch and adoption timelines.
AP301 represents the "near-term catalyst." Positioned as a potential best-in-class oral iron-based phosphate binder for treating hyperphosphatemia in dialysis patients, it offers several advantages, including high phosphate binding efficiency, no need for chewing, and minimal gastrointestinal absorption due to its non-systemic action. In August 2026, the New Drug Application (NDA) for AP301 in China was accepted by the National Medical Products Administration (NMPA). Furthermore, patient enrollment has been completed for its global Phase III multi-regional clinical trial. The valuation logic for AP301 is thus shifting from "probability of clinical success" to "regulatory review, launch timeline, and commercial uptake."
AP306 represents "product advancement and globalization." It functions by simultaneously inhibiting three key phosphate transporters – NaPi-IIb, PiT-1, and PiT-2 – targeting the root cause of phosphate absorption in the gut. Data from its completed Phase II trial showed that AP306 could effectively control average serum phosphorus levels within the optimal range recommended by KDIGO. The average daily maintenance dose was approximately 300 mg, which is roughly one-sixteenth of the dose of sevelamer carbonate used as the active comparator in the trial. AP306 has been granted Breakthrough Therapy Designation by the NMPA, and the first patient has been randomized and dosed in its global Phase IIb study. The commercial success of Ardelyx has already confirmed that non-binder mechanisms can gain both regulatory and clinical acceptance in the hyperphosphatemia market. AP306, with its distinct pan-phosphate transporter inhibition mechanism, holds the potential to further advance this treatment field through product iteration.
AP303 and AP308 represent ALEBUND's "long-term growth ceiling." AP303 is an oral dual PPAR agonist designed to delay or halt the progression of CKD, with potential applications across multiple major indications including FSGS, diabetic kidney disease (DKD), IgA nephropathy, and autosomal dominant polycystic kidney disease (ADPKD). Having completed Phase I clinical trials, its Phase II IND applications in both China and the U.S. have been cleared, and trial initiation is being prepared. The rapid commercial uptake of Travere's products in FSGS and IgA nephropathy has demonstrated that once a differentiated drug targeting glomerular diseases completes clinical validation, it can quickly penetrate the specialty market. Although AP303 is at an earlier stage, its "basket" development strategy covering several high-proteinuria kidney diseases leaves ample room for clinical proof-of-concept across a broad range of indications.
AP308 is an engineered recombinant IgA protease designed to directly cleave and clear pathogenic IgA complexes that have already formed. Compared to existing therapies that reduce IgA production or suppress downstream injury, its mechanism targets the disease's root cause, aiming for a functional cure for IgA nephropathy. Its therapeutic potential has been validated in preclinical research published in Kidney International.
From the commercialized Mircera®, to the soon-to-launch AP301, to the globally-clinical-stage AP306, and the disease-modifying candidates AP303 and AP308, ALEBUND-B has constructed a product ladder with clear strategic layers. This tiered pipeline structure ensures that the company's long-term value is not dependent on the success of any single product or clinical milestone.
The Real Advantage of a Vertical Focus: Compounding Capabilities
The core value of a vertical-specialty biopharma is not merely the aggregation of products, but the continuous reuse and compounding growth of R&D, clinical, and commercial resources within the same disease area. For ALEBUND, the target endpoints for its various products are highly overlapping, primarily concentrated among nephrology departments, dialysis centers, and CKD patients requiring long-term management. The hospital network established through Mircera® can directly support the launch and promotion of AP301. The clinical resources and expert relationships built in the hyperphosphatemia space can be leveraged for AP306's development. Furthermore, the professional brand recognition among nephrologists and research institutions will facilitate the clinical execution of AP303 and AP308.
As the product matrix expands, a single commercial channel serves multiple drugs, and the R&D team's understanding of disease mechanisms, clinical endpoints, and patient recruitment can be applied across different pipeline assets. This creates not just simple economies of scale, but a continuously strengthening operational leverage specific to the specialty. This is the industry rule validated by overseas specialists like Travere, Calliditas, and Ardelyx: once a company in a vertical niche successfully navigates its first product through clinical development and commercialization, its subsequent growth momentum is fueled not only by new product sales but also by the reusable value of its accumulated R&D knowledge, physician networks, and market access capabilities.
Long-term Shareholder Support Signals Growing Market Recognition
The global re-rating of kidney disease assets is now influencing the Chinese market, a trend clearly reflected in ALEBUND's share price performance and capital actions. On August 5th, following Travere's strong quarterly results, ALEBUND's share price surged over 15% intraday before closing up 13.07% at HKD 33.22. Although the two companies' products are not directly competitive, the market's positive response suggests that investors are beginning to benchmark Chinese assets with similar rarity against the commercial progress of global kidney disease innovators.
Continuous share accumulation by a long-standing shareholder provides a more definitive signal of confidence. Public filings show that on July 17th, Tencent Holdings increased its stake in ALEBUND by 238,500 shares at an average price of approximately HKD 27.97 per share, for a total consideration of about HKD 6.67 million. Following this purchase, Tencent's total holding rose to approximately 22.9162 million shares, representing about 10.09% of the company's issued H shares. Tencent is not a short-term investor who entered post-IPO but rather an early long-term shareholder who participated in multiple financing rounds. Its decision to continue buying shares in the secondary market after the listing represents a tangible, vote-of-confidence from an existing shareholder in the company's future regulatory submissions, clinical progress, and commercialization prospects.
A Model for China's Vertical-Specialty Biopharma
Travere, Calliditas, Ardelyx, Akebia, and Chinook have each followed distinct growth trajectories: some have built revenue curves through blockbuster product launches, others have reshaped treatment paradigms with novel mechanisms, and some have become acquisition targets for major pharmaceutical companies due to their high-quality pipelines. ALEBUND-B does not need to replicate any of them. It is forging its own distinctive path: using Mircera® to pre-establish a commercial foundation, leveraging AP301 as its near-term value catalyst, employing AP306 to connect with global development resources, and extending towards the frontier of disease modification with AP303 and AP308.
The significance of this interim report extends far beyond the 8.6-fold revenue growth. It signifies the simultaneous maturation of three core competencies: a market-validated specialty commercialization capability, the ability to create and monetize innovative asset value recognized by international partners, and the continuous R&D strength to cover the entire disease cycle. When a biotech simultaneously possesses stable product revenue, core assets nearing commercialization, deeply integrated global partnerships, a clearly tiered long-term pipeline, and substantial cash reserves, its value proposition has fundamentally shifted. On China's kidney disease innovation track, a vertically integrated biopharma with global competitiveness is now emerging.